Keros Therapeutics Stock Investor Sentiment

KROS Stock  USD 10.94  0.03  0.27%   
Slightly above 54% of Keros Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that many traders are impartial. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.

Comfort Level 46

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Keros Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Keros Therapeutics.

Keros Historical Sentiment

Although Keros Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Keros, such as negative comments on social media and news outlets, may cause fear in the market and push Keros Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Keros.
  

Keros Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Keros Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Keros Therapeutics Historical Investor Sentiment

Investor biases related to Keros Therapeutics' public news can be used to forecast risks associated with an investment in Keros. The trend in average sentiment can be used to explain how an investor holding Keros can time the market purely based on public headlines and social activities around Keros Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Keros Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Keros Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Keros Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Keros Therapeutics.
over two months ago at seekingalpha.com         
Keros stock plunges 76 percent on drug study halt over safety concerns
seekingalpha News
over two months ago at bizjournals.com         
Lexington biotechs stock crashes after partial drug trial pause
bizjournals News
over two months ago at globenewswire.com         
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society ...
Macroaxis News: globenewswire.com
over two months ago at gurufocus.com         
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American ...
Gurufocus Stories at Macroaxis
over two months ago at thelincolnianonline.com         
Keros Therapeutics Buy Rating Reiterated at Guggenheim
news
over two months ago at investing.com         
Keros Therapeutics stock Buy rating intact, price target raised after Takeda deal
Investing News at Macroaxis
over two months ago at thelincolnianonline.com         
Parkman Healthcare Partners LLC Has 24.49 Million Position in Keros Therapeutics, Inc.
news
over two months ago at thelincolnianonline.com         
Point72 Asia Singapore Pte. Ltd. Boosts Position in Keros Therapeutics, Inc.
news
over two months ago at investing.com         
Keros Therapeutics stock outlook strong, BofA keeps Buy rating after licensing deal with Takeda
Investing News at Macroaxis
over two months ago at benzinga.com         
Keros Therapeutics Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept Analys...
benzinga news
over two months ago at bizjournals.com         
Lexington biotech gets 200M upfront from Takeda for anemia drug
bizjournals News
over two months ago at gurufocus.com         
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros ...
Gurufocus Stories at Macroaxis
over two months ago at thelincolnianonline.com         
HighVista Strategies LLC Purchases 12,899 Shares of Keros Therapeutics, Inc.
news
over two months ago at finance.yahoo.com         
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therape...
Yahoo News
over three months ago at news.google.com         
Keros Therapeutics CEO to Present at Major Healthcare Conferences in December - StockTitan
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Keros Therapeutics that are available to investors today. That information is available publicly through Keros media outlets and privately through word of mouth or via Keros internal channels. However, regardless of the origin, that massive amount of Keros data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Keros Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Keros Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Keros Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Keros Therapeutics alpha.

Keros Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Keros Therapeutics Inc Halts Dosing in TROPOS Trial Due to Safety Concerns
12/12/2024
2
Heres Why Keros Therapeutics is Poised for a Turnaround After Losing -39.17 percent in 4 Weeks
01/16/2025
3
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance ...
01/21/2025
4
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc.
01/22/2025
5
KEROS ALERT Bragar Eagel Squire, P.C. is Investigating - GlobeNewswire
01/24/2025
6
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
01/28/2025
7
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compounds Potential as a Therapeutic...
02/06/2025
8
Acquisition by Rovaldi Christopher of 60000 shares of Keros Therapeutics subject to Rule 16b-3
02/18/2025

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.